SOURCE: World Street Fundamentals

May 09, 2011 10:22 ET

A Brighter Decade Ahead for Biotech -- In-Depth Research Featuring GlaxoSmithKline and NPS Pharmaceuticals

HONG KONG--(Marketwire - May 9, 2011) - released its industry report highlighting GlaxoSmithKline (NYSE: GSK) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP). Full fundamental and technical analysis is available at

The global pharmaceutical market is expected to experience wide changes, with trends growing towards the Asia-Pacific region. A favorable regulatory environment has started to emerge in India, China, Malaysia, South Korea and Indonesia; drawing the attention of larger API product providers. This new competition within an already fast-paced economy has closed the gap between product cost and disposable income of consumers -- a change that is expected to drive long-term growth within the global marketplace.

Global pharmaceutical market sales are expected to grow at a 4 - 7% compound annual growth rate (CAGR) through 2013, largely driven via growing access to health-care in emerging economic regions. Short-term growth within the sector will be fueled by the US market, as it remains the largest pharmaceutical market in the world. A large focus on R&D in biotechnology, special drugs and generic drugs will remain a strong catalyst to meet 2011 targets of $315 billion in sales volume within the United States alone.

World Street Fundamentals has highlighted GlaxoSmithKline for its recent FDA approval of Horizant (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. It is the first medication in its class to be approved for the treatment of moderate-to-severe primary Restless Legs Syndrome. Discovered and developed by XenoPort, Horizant is a new chemical entity that utilizes the body's nutrient transport mechanisms that are believed to facilitate its absorption into the body. The entire report on GlaxoSmithKline (NYSE: GSK) is available here:

World Street has highlighted NPS Pharmaceuticals for its focus on bringing biopharmaceuticals to patients with rare disorders and few, if any, therapeutic options. The company is advancing two Phase 3 registration programs, GATTEX® (teduglutide) in short bowel syndrome (SBS) and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) in hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical. The entire report on NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is available here:

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets around the world.

Contact Information